| Title |
Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
|
|---|---|
| Published in |
PLOS ONE, January 2012
|
| DOI | 10.1371/journal.pone.0030815 |
| Pubmed ID | |
| Authors |
Li Shen, Michael Ciesielski, Swathi Ramakrishnan, Kiersten M. Miles, Leigh Ellis, Paula Sotomayor, Protul Shrikant, Robert Fenstermaker, Roberto Pili |
| Abstract |
Immunosuppressive factors such as regulatory T cells (Tregs) limit the efficacy of immunotherapies. Histone deacetylase (HDAC) inhibitors have been reported to have antitumor activity in different malignancies and immunomodulatory effects. Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model. |
Mendeley readers
The data shown below were compiled from readership statistics for 146 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| Austria | 1 | <1% |
| France | 1 | <1% |
| Japan | 1 | <1% |
| Spain | 1 | <1% |
| Unknown | 140 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 31 | 21% |
| Student > Ph. D. Student | 26 | 18% |
| Student > Master | 17 | 12% |
| Student > Bachelor | 15 | 10% |
| Student > Doctoral Student | 9 | 6% |
| Other | 20 | 14% |
| Unknown | 28 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 23% |
| Biochemistry, Genetics and Molecular Biology | 23 | 16% |
| Agricultural and Biological Sciences | 20 | 14% |
| Immunology and Microbiology | 11 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 6% |
| Other | 14 | 10% |
| Unknown | 35 | 24% |